Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
Recruiting
Observational Study
Age Related Macular Degeneration
Exudative Age-Related Macular Degeneration
Anti Vascular Endothelial Growth Factor
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 45 – 90
- Sex
- Any
- Study type
- Observational
- Participants needed
- 54 (estimated)
- Sponsor
- Saglik Bilimleri Universitesi · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)
* who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)
* for whom intravitreal injection has already been clinically…
Contacts